Evidence map›Paper›PMID 42660999›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Integrated

Xueqian Yang, Linyang Gan, Ximin Shi, Meiqi Wu, Enhui Li, Yuke Zhang, Zhixin Hao, Zhenghai Huang, Haiqun Xing, Xiaowei Liu and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07400224 (Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07400224 phase1 / phase2recruitingnot on this map

Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease

TypeinterventionalSponsorPeking Union Medical College HospitalRan2022 to 2028Enrolled600ConditionsHyperthyroidism, Autoimmune, Cardiovascular Abnormalities, Malignant TumorArmsAl18F-NOTA-FAPI PET/CT(or PET/MRI)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xueqian YangDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Linyang GanDepartment of Ophthalmology, Peking Union Medical College Hospital, Beijing Key Laboratory of Fundus Diseases Intelligent Diagnosis & Drug/Device Development and Translation, Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Ximin ShiDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Meiqi WuDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Enhui LiShanghai United Imaging Healthcare Co., Ltd., 201807, Shanghai, China.
Yuke ZhangDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Zhixin HaoDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Zhenghai HuangDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Haiqun XingDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China. 15801255152@163.com.
Xiaowei LiuDepartment of Ophthalmology, Peking Union Medical College Hospital, Beijing Key Laboratory of Fundus Diseases Intelligent Diagnosis & Drug/Device Development and Translation, Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Li HuoDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China. huoli@pumch.cn.ORCID http://orcid.org/0000-0003-1216-083X

Funding

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences CIFMS-2024-I2M-ZD-001National High Level Hospital Clinical Research Funding 2025-PUMCH-A-056National Key R&D Program of China 2024YFC2419400National Natural Science Foundation of China 82402335National Natural Science Foundation of China U24A20758Natural Science Foundation of Beijing Municipality L242062
6 · The paper itself

Abstract

purposeThis study aimed to evaluate the value of integrated

methodsA total of 33 TAO participants were prospectively enrolled and underwent intergrated

resultsVOIs delineation demonstrated good interobserver and intraobserver agreement, with DSC of 0.850 (95% CI: 0.815-0.886), 0.880 ± 0.068 (95% CI: 0.831, 0.929), and 0.901 (95% CI: 0.838, 0.965), respectively. All PET/MRI quantitative parameters showed high reproducibility (ICC > 0.907). PET/MRI correlations were generally weak at patient-level but substantially stronger at eye-level, particularly for associations between PET metrics and T2WI-, α-, D-, and MD- derived features. At the eye level, SUV

conclusionIntegrated CLINICAL

trial registrationNCT07400224 (2/3/2026).

Indexed as

18F-NOTA-FAPI-04 PET/MRICASDiffusion kurtosis imagingIntravoxel incoherent motionThyroid-associated ophthalmopathy

Identifiers

PMID42660999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.